Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phenylephrine topical gel - Plethora Solutions

Drug Profile

Phenylephrine topical gel - Plethora Solutions

Alternative Names: PSD 503; PSD503 (phenylephrine 20% w/w) - Plethora Solutions

Latest Information Update: 28 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plethora Solutions
  • Class Antihypotensives; Decongestants; Ethanolamines; Gene therapies; Mydriatics; Phenethylamines; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stress incontinence

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-II for Stress incontinence in United Kingdom (Topical)
  • 24 Jan 2012 Plethora Solutions terminates phase II trial in Stress incontinence in United Kingdom
  • 01 Jun 2010 Phase-II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top